Modality
Cell Therapy
MOA
FcRni
Target
SMN2
Pathway
Autophagy
GISTEndometrial CaADPKD
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
Feb 2021
→ Sep 2028
Phase 1Current
NCT05756128
2,845 pts·Endometrial Ca
2021-02→2028-09·Completed
2,845 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-212.5y awayInterim· Endometrial Ca
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Complet…
Catalysts
Interim
2028-09-21 · 2.5y away
Endometrial Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05756128 | Phase 1 | Endometrial Ca | Completed | 2845 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA |